• Common manifestations include lytic lesions in bones that cause pain and/or fractures, renal insufficiency, hypercalcemia, anemia, and recurrent infections. (merckmanuals.com)
  • Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (merckmanuals.com)
  • Stem Cell Transplantation In Multiple Myeloma. (myeloma.org.uk)
  • Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. (myeloma.org.uk)
  • Current treatments for renal failure due to multiple myeloma. (myeloma.org.uk)
  • Multiple myeloma: managing a complex blood cancer. (myeloma.org.uk)
  • Multiple myeloma is a bone marrow disease characterized by the presence of malignant plasma cells, & abnormal serum &/or urine immunoglobulin secondary to clonal plasma cell expansion. (mims.com)
  • Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of transformed monoclonal plasma cells in the bone marrow (BM) [ 1 ]. (biomedcentral.com)
  • Cell therapy, including chimeric antigen receptor T-cell (CAR-T) therapies, BCMA-targeted antibodies, and bispecific T-cell engagers, may be some of the most promising therapeutics to be added to the frontline treatment of multiple myeloma (MM). Clinical trials are underway to assess some of these therapies as part of the initial therapy for myeloma. (cancertherapyadvisor.com)
  • A rare, aggressive variant of MULTIPLE MYELOMA characterized by the circulation of excessive PLASMA CELLS in the peripheral blood. (lookformedical.com)
  • It occurs in 10-15% of patients with full-blown multiple myeloma but can also be seen when the affected patient has less than 10% bone marrow plasma cells, the quantity typically required to make a diagnosis of myeloma. (askhematologist.com)
  • A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants. (biomedcentral.com)
  • Subsequently, his serum creatinine stabilized at 2.1 mg/dL (185.64 μmol/L). Seventeen months after the second hematopoietic stem cell transplant, he was initiated on carfilzomib for relapse of multiple myeloma. (biomedcentral.com)
  • Because impairment of kidney function in patients with multiple myeloma (MM) can be caused by a variety of conditions, ascertaining the etiology of kidney dysfunction in patients with MM represents a challenging task for the practicing nephrologist. (biomedcentral.com)
  • With more than 6,000 transplants of cord blood from related and unrelated donors performed thus far, cord blood has emerged as an acceptable, alternative source of HPCs that has some advantages over adult sources of HPCs and the availability of which represents an important development in the field. (nationalacademies.org)
  • My principle research interests are in the prevention and therapy of graft-versus-host disease (GVHD) and in the use of graft-versus-leukemia to eradicate blood disorders. (harvard.edu)
  • Until the year 2000, the standard therapy for MM was melphalan- or doxorubicin-based regimens with corticosteroids. (biomedcentral.com)
  • elicits antiproliferative and proapoptotic activities in vitro in solid and hematologic tumor cells. (medscape.com)
  • Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
  • CD8 + CTL-recognizing minor H antigens on tumor cells can be isolated posttransplant and could contribute to the graft- versus -tumor effect. (aacrjournals.org)
  • For Phase 1 dose expansion, the AXL expression cutoff is ≥ 1+ in ≥ 10% tumor cells. (marycrowley.org)
  • A cell line derived from cultured tumor cells. (lookformedical.com)
  • According to research presented during the ASCO20 Virtual Scientific Program (and based on real-world results from a study on patients with newly diagnosed disease who were in the Connect MM Registry), patients with renal impairment should now be considered for inclusion in clinical trials, as well as for treatment with lenalidomide-bortezomib-dexamethasone (RVd). (cancertherapyadvisor.com)
  • I agree that patients who are newly diagnosed with MM and have kidney function impairment due to this should be treated with effective therapy and be considered for treatment for VRd. (cancertherapyadvisor.com)
  • Additionally, I agree that patients with newly diagnosed myeloma and renal impairment should be considered for inclusion in clinical trials. (cancertherapyadvisor.com)
  • Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (merckmanuals.com)
  • BCMA, a member of the tumor necrosis factor (TNF) superfamily, is exclusively expressed in a subpopulation of B cells, normal plasma cells, and malignant plasma cells. (biomedcentral.com)
  • The most common type of amyloidosis and used to be called primary amyloidosis results when light chains are produced in excess by clonal or frankly malignant plasma cells. (askhematologist.com)
  • The addition of daratumumab to frontline VRd resulted in an increase in complete remission (CR) from 32% to 42% at the end of postautologous stem cell transplant (ASCT) consolidation, which met the primary endpoint of the study. (cancertherapyadvisor.com)
  • Although many plasma cell disorders have been reported in patients with POEMS syndrome, most patients are seen with osteosclerotic myeloma or monoclonal gammopathy of unknown significance. (medscape.com)
  • RXR Agonists Enhance Lenalidomide Anti-Myeloma Activity and T Cell Functions while Retaining Glucose-Lowering Effect. (dukecancerinstitute.org)
  • In view of the previously reported association of bortezomib with thrombotic microangiopathy, the temporal association of the clinical picture with the initiation of carfilzomib, and the partial resolution of symptoms after discontinuation of the drug, we conclude that carfilzomib may have precipitated a case of clinically evident renal thrombotic microangiopathy in our patient. (biomedcentral.com)
  • After the second hematopoietic stem cell transplant, he developed acute kidney injury secondary to septic shock and required dialysis for 4 weeks. (biomedcentral.com)
  • The choice of chemotherapy depends on several factors, including the patient's performance status, age, renal function, desire for inpatient or outpatient therapy, and likelihood of receiving future autologous stem cell transplantation. (medscape.com)
  • Neupogen is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. (medicines.org.uk)
  • For example, a study using human Burkitt lymphoma cells found that oxidative stress actually interferes with the ability of the chemotherapy drugs doxorubicin, cisplatin, etoposide, and cytarabine to cause cancer cell death. (pinestreetfoundation.org)
  • The authors of the above-mentioned study on Burkitt lymphoma cells and chemotherapy suggest that including antioxidants in the treatment protocol may enhance chemotherapy-induced apoptosis and phagocytosis. (pinestreetfoundation.org)
  • 2000) A second study, involving the chemotherapy drugs etoposide and calcimycin, confirms this finding: Human Burkitt's lymphoma cells were unable to die quickly by apoptosis in the presence of oxidative stress and instead died using the slower and messier method of necrosis. (pinestreetfoundation.org)
  • Many research studies, encompassing cell culture tests in the laboratory and also animal and some human studies, are coming to a conclusion often very different from the conventional perspective that chemotherapy and antioxidants should never be combined. (pinestreetfoundation.org)
  • One example is a human study in which researchers discovered that higher levels of the antioxidant selenium in the blood of patients with aggressive B-cell non-Hodgkin's lymphoma correlated with increased achievable doses of anthracycline based chemotherapy, better treatment response, achievement of long term remission, and longer overall survival. (pinestreetfoundation.org)
  • Antibody- and T-cell-based approaches to targeting of B-cell maturation antigen have shown efficacy. (merckmanuals.com)
  • Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART before the Horse. (myeloma.org.uk)
  • There is an unmet need to develop novel therapies for refractory/relapsed MM. In the past few years, chimeric antigen receptor (CAR)-modified T cell therapy for MM has shown promising efficacy in preclinical and clinical studies. (biomedcentral.com)
  • Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel immunotherapy which modifies T cells with CAR, an artificial fusion protein that incorporates an extracellular antigen recognition domain, a transmembrane domain, and an intracellular domain including costimulation and signaling components [ 4 , 5 ]. (biomedcentral.com)
  • Several antigens have been used as targets for CAR-T cell therapy against MM, including B cell maturation antigen (BCMA), CD19, CD138, signaling lymphocytic activation molecule 7 (SLAM7), and immunoglobulin light chains. (biomedcentral.com)
  • Two main advantages of BCMA as an antigen for CAR-T therapy are the potential reduction of on-target/off-tumor toxicity and the lack of antigen-dependent reduction in CAR-T cell expansion [ 16 ]. (biomedcentral.com)
  • 2003). After the early success of transplantation of cord blood from related donors, cord blood banks were established to provide rapidly accessible, human leukocyte antigen (HLA)-typed units predominantly for transplantation of HPCs from unrelated donors. (nationalacademies.org)
  • CRS generally occurs with therapies that lead to highly activated T cells, like chimeric antigen receptor T cells or in the case of bispecific T-cell engaging antibodies. (bmj.com)
  • In patients with renal failure or highly aggressive disease, therapy with vincristine, Adriamycin (doxorubicin), and dexamethasone (VAD) may be preferred. (medscape.com)
  • Doxorubicin liposomal is a pegylated formulation that protects the liposomes and, thereby, increases blood circulation time. (medscape.com)
  • In cultured primary fibroblasts and cancer cells, the chemotherapeutic drug doxorubicin causes mtDNA damage and release, which leads to cGAS STING dependent ISG activation. (regenerativemedicine.net)
  • In addition, mtDNA stress in TFAM-deficient mouse melanoma cells produces tumours that are more resistant to doxorubicin in vivo. (regenerativemedicine.net)
  • Differential diagnoses include cryoglobulinemia, warfarin-induced necrosis, purpura fulminans, emboli to the skin, thrombocythemia, protein C deficiency, Sneddon syndrome, and skin ulcers in patients with sickle cell anemia or hemolytic anemia. (medscape.com)
  • Development of peripheral neuropathy is a limiting factor. (medscape.com)
  • A decreased incidence of peripheral neuropathy has been observed with SC administration compared with the IV route. (medscape.com)
  • However soon after the drug's release in Europe reports linked thalidomide to causing peripheral neuropathy in adult patients (which prevented its licensing and general release in the USA) as well as being behind the occurrence of a high and sudden increase of rare birth defects [ 3 , 5 - 8 ]. (hindawi.com)
  • Dr. Kelsey was concerned about the peripheral neuropathy side effect that had been experienced and reported in some patients in Europe following thalidomide exposure [ 3 , 5 , 25 , 26 ]. (hindawi.com)
  • In this report, we summarize the case of a patient with MM status post autologous HSCT and chronic kidney disease who experienced worsening hypertension along with a substantial increase in proteinuria shortly after the initiation of carfilzomib for the treatment of refractory disease. (biomedcentral.com)
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
  • Conditions characterized by the presence of M protein (Monoclonal protein) in serum or urine without clinical manifestations of plasma cell dyscrasia. (lookformedical.com)
  • Giant cell tumors (GCT) of the bone are aggressive and are recognised for variable clinical behaviour, which is not always related to radiographic or histological appearance [1]. (jbstjournal.com)
  • Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies? (bmj.com)
  • Myelofibrosis (MF) is a hematopoietic stem cell malignancy classified as a myeloproliferative neoplasm (MPN). (cancernetwork.com)
  • A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. (lookformedical.com)
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
  • Immunotherapy utilizing T cell immunity has become a new treatment to eliminate cancer cells. (biomedcentral.com)
  • The aim of the academic journal is to provide a platform for researchers, scientists, physicians, and other health professionals to find latest research information in the areas of stem cell research, transplantations such as stem cell transplantation, transplantation immunology, kidney transplantation and its treatment. (slideshare.net)
  • Based on its pathophysiology and the resemblance of CRS to sepsis and septic shock, as well as based on the principles of initiation of continuous renal replacement therapy (CRRT) in sepsis, we propose the rationale of using CRRT therapy as an adjunct treatment in CRS where all the other approaches have failed in controlling the clinically significant manifestations. (bmj.com)
  • The goal of treatment of this tumor at the distal radius is complete removal of the tumor and reconstruction of the bone defect in order to preserve maximum function of the wrist joint. (jbstjournal.com)
  • Goals of treatment are to achieve satisfactory removal of the tumor, lessen the chance of local recurrence and to preserve as much wrist function as possible. (jbstjournal.com)
  • Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome is a rare multisystemic disease that occurs in the setting of a plasma cell dyscrasia. (medscape.com)
  • Enlargement of the lymph nodes and spleen is secondary to changes consistent with Castleman disease (giant angiofollicular hyperplasia, multicentric plasma cell variant) in most patients. (medscape.com)
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
  • Neupogen is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs). (medicines.org.uk)
  • The mobilisation and apheresis procedures should be performed in collaboration with an oncology-haematology centre with acceptable experience in this field and where the monitoring of haematopoietic progenitor cells can be correctly performed. (medicines.org.uk)
  • As the cells reproduce, they commit to a particular task or cell line and become known as committed progenitor cells . (nationalacademies.org)
  • These committed progenitor cells are difficult to discern from the original multipotent cells but can be cultured to form colonies of specific types of blood cells (Guyton and Hall, 2000). (nationalacademies.org)
  • Umbilical cord blood is a rich source of these committed progenitor cells and, presumably, multipotent HPCs (Knudtzon, 1974). (nationalacademies.org)
  • Giant cell tumor is a benign bone tumor, locally aggressive with low malignant potential. (jbstjournal.com)
  • Giant cell tumor (GCT) of bone is a benign but locally aggressive tumor with tendency for local recurrence [2]. (jbstjournal.com)
  • It is closely associated with B cell-activating factor of the TNF family (BAFF) receptor, transmembrane activator, calcium modulator, and cyclophilin ligand interactor (TACI) [ 14 ]. (biomedcentral.com)
  • BCMA is not present in other hematological cells like hematopoietic stem cells or other tissues. (biomedcentral.com)
  • Therefore, we propose that damage to and subsequent release of mtDNA elicits a protective signalling response that enhances nDNA repair in cells and tissues, suggesting that mtDNA is a genotoxic stress sentinel. (regenerativemedicine.net)
  • Overview of Plasma Cell Disorders Plasma cell disorders are a diverse group of disorders of unknown etiology characterized by Disproportionate proliferation of a single clone of B cells Presence of a structurally and electrophoretically. (merckmanuals.com)
  • Vincristine inhibits cellular mitosis by inhibition of intracellular tubulin function, binding to microtubules, and synthesis of spindle proteins in the S phase. (medscape.com)
  • Reversible proteasome inhibition disrupts pathways supporting cell growth, thus decreasing cancer cell survival. (medscape.com)
  • Also, injection of mice with LPS induced OPG manufacturing HSP90 inhibition particularly in lymph nodes, in particular in substantial endothelial chemical compound library venule cells, but not in other organs. (cox-inhibitors.com)
  • Extramedullary hematopoiesis (EMH) is likely the result of abnormal trafficking of hematopoietic stem cells (HSC) from the bone marrow to organs such as the spleen, liver, and lung, causing organomegaly and sometimes organ dysfunction. (cancernetwork.com)
  • These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin. (lookformedical.com)
  • Abnormal immunoglobulins synthesized by atypical cells of the MONONUCLEAR PHAGOCYTE SYSTEM. (lookformedical.com)
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
  • A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. (lookformedical.com)
  • Diagnosis typically requires demonstration of M-protein (sometimes present in urine and not serum but rarely absent entirely) and/or light-chain proteinuria, and excessive plasma cells in the bone marrow. (merckmanuals.com)
  • Biol Blood Marrow Transplant. (myeloma.org.uk)
  • Any discrete, presumably solitary, mass of neoplastic PLASMA CELLS either in BONE MARROW or various extramedullary sites. (lookformedical.com)
  • Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. (lookformedical.com)
  • Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. (lookformedical.com)
  • In 15 to 20% of patients, plasma cells secrete only Bence Jones protein. (merckmanuals.com)